Tag
Liz Seegert, AHCJ’s topic leader on aging, contributed to this article. Federal policy experts and the influential Institute for Clinical…

Part two of two parts; the first ran Thursday, June 10. There’s still a great deal we don’t yet understand…

Part one of two parts; the second runs tomorrow, Friday, June 11. You might think that the first new drug…

A recent announcement by drugmaker Eli Lilly that its drug donanemab slowed the progression of Alzheimer’s by nearly one-third is…

We don’t yet know the severity of COVID-19’s long-term effects on the brain, but a group of international researchers is…

Could an Alzheimer’s drug finally be on the horizon? Possibly ― if the FDA agrees with data from several Biogen…

How do you wrap your arms around a topic as big as dementia to create a five-part series that’s cohesive,…

Can your eyes predict the onset of Alzheimer’s disease (AD) years before cognitive symptoms appear? Findings in a recent study…

While scientists are getting closer to understanding the various causes and risk factors for Alzheimer’s disease and dementias, there’s still…
